Human Immunodeficiency Virus (HIV) primarily transmits through condomless sexual contact, shared injection needles, or mother-to-child vertical exposure. Modern biomedical advances have introduced highly effective pharmacological strategies alongside consistent condom usage and routine screening: Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP), transforming global HIV prevention.
Medical Mechanisms of PrEP
PrEP is intended for HIV-negative individuals who anticipate potential exposure risk. By maintaining adequate systemic and mucosal concentrations of antiretroviral drugs prior to exposure, any invading viral particles are intercepted. The medications inhibit viral reverse transcriptase and integrase, preventing HIV from integrating into host genetic material and replicating, thereby halting permanent infection.
PrEP Regimens and Efficacy
Standard regimens comprise dual-antiretroviral agents combining Tenofovir (TDF or TAF) with Emtricitabine (FTC). When taken consistently as prescribed, PrEP reduces the risk of acquiring HIV from sexual contact by over 90%.
- Daily Regimen: One tablet taken once daily. Optimal tissue levels are established after approximately 7 consecutive days for rectal mucosa and around 20 days for vaginal tissue. Recommended for individuals with regular sexual activity or unpredictable schedules.
- On-Demand (2-1-1 / Event-Driven) Regimen: Indicated for cisgender men who have sex with men. Involves a loading dose of 2 tablets taken 2 to 24 hours prior to anticipated sexual intimacy, followed by 1 tablet 24 hours later, and a final tablet 48 hours after the initial dose. Requires medical counseling before initiation.
PEP: Post-Exposure Emergency Intervention
PEP (Post-Exposure Prophylaxis) is an emergency antiretroviral protocol administered following an accidental or unexpected high-risk exposure (e.g., condom rupture, non-consensual contact, or occupational needle injury). PEP must be initiated as early as possible within the critical 72-hour golden window and taken continuously for 28 days.
- Triple Therapy: PEP typically utilizes a robust three-drug regimen (e.g., Biktarvy or equivalent integrase-inhibitor-based combinations) to suppress viral replication before integration occurs.
- Adherence is Critical: Missing doses diminishes protective efficacy. If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose—never take a double dose.
Pre-Prescription Screening & Follow-up Protocols
- Confirm HIV-Negative Status: Baseline antibody and antigen testing must verify the absence of pre-existing infection to avoid drug-resistant viral mutations.
- Renal & Liver Function Assessment: Baseline eGFR/creatinine evaluation and hepatitis B/C screening ensure safe medication metabolism.
- Comprehensive STI Screening: PrEP and PEP only protect against HIV, not bacterial STIs such as syphilis, gonorrhea, or chlamydia, nor viral conditions like HPV or herpes. Routine condom use remains essential.
- Quarterly Clinical Monitoring: Regular 3-month follow-up visits assess tolerability, verify ongoing HIV negativity, and monitor organ function.
Frequently Asked Questions (FAQ)
Q1: Does taking PrEP protect against other sexually transmitted infections?
No. PrEP is exclusively effective against HIV. Other sexually transmitted infections (syphilis, gonorrhea, chlamydia, genital warts) require barrier protection (condoms) and prompt medical screening.
Q2: What should I do if I suspect an exposure occurred yesterday?
Seek emergency medical assessment immediately for PEP. PEP is most effective when started as soon as possible and must be initiated within 72 hours of exposure.
References
- Centers for Disease Control and Prevention (CDC). Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – Clinical Practice Guideline. 2021.
- World Health Organization (WHO). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. Geneva: WHO, 2022.
- Molina JM, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237-2246.